Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, shares some insights into a study evaluating the use of RO7443904, a bispecific antibody-like fusion protein, in combination with glofitamab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.